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Summary
Objective: RDC1 is a class A orphan G-protein coupled receptor of unknown function. The purpose of this study was to identify
compound RDC1 agonists and use these as tools to determine the effect of RDC1 activation in human chondrocytes and cartilage explant
tissue.
Methods: Computational chemistry was employed to build a homology model of the RDC1 receptor. A virtual screen of in-house compounds
was then performed and positive hits screened for their ability to invoke a Ca2þ response in a recombinant RDC1 HEK293 cell line, as mea-
sured by FLIPR. The effect of RDC1 activation on human chondrocytes and cartilage explant gene expression was determined by quantitative
real-time polymerase chain reaction (PCR), and these effects validated as being mediated by RDC1 using siRNA antisense.
Results: Tissue expression proﬁling demonstrated that RDC1 expression was predominant in cartilage tissue. Treatment of human primary
chondrocytes with RDC1 agonist induced a Ca2þ response, suggesting the receptor is active in this tissue type. Treatment for 24 h with
RDC1 agonist led to altered expression of a number of genes associated with chondrocyte hypertrophy and increased matrix degradation
in human primary chondrocytes, and elevated total matrix metalloproteinase (MMP) activity in cartilage explant. Transfection with RDC1
siRNA caused a >90% reduction in human primary chondrocyte RDC1 expression and signiﬁcantly reduced the impact of RDC1 agonist
on the previously identiﬁed RDC1-regulated genes.
Conclusions: RDC1 activation in human chondrocytes and cartilage explant leads to changes in gene expression and activity associated with
chondrocyte hypertrophy, angiogenesis and increased matrix degradation, suggesting signalling via the RDC1 receptor may play an important
role in the early development of osteoarthritis (OA).
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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In the drug discovery process G-protein coupled receptors
(GPCRs) have proven to be excellent targets for therapeutic
modulation, with greater than 50% of drugs in today’s mar-
ket targeting GPCR signalling. However, despite the identi-
ﬁcation of over 800 human GPCRs by the human genome
project, more than half are termed orphan GPCRs since
the native ligand is unknown. The identiﬁcation of a com-
pound that can activate an orphan GPCR, a process re-
ferred to as deorphanisation, is crucial for target validation
studies in order to determine if the GPCR has a functional
role in the disease state.
RDC1 is a class A orphan GPCR that shares homology
with chemokine receptors, 33% homology to CXCR2 and
31% homology to CXCR4. However, largely because the
physiological ligand is unknown, the role of RDC1 has not
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posed. Similar to other chemokine receptors such as
CCR3 and CCR5, it has been reported to be a co-receptor
for the HIV virus1. In addition it is upregulated by TNFa2
and the steroid hormone progesterone3, whilst its upregula-
tion in hypoxic tissue has led to the suggestion that it
may mediate the hypotensive effects of adrenomedullin
peptides4e6.
It has previously been suggested that RDC1 may func-
tion as a receptor for adrenomedullin and the structurally
related peptide, calcitonin gene-related peptide (CGRP)4,
and therefore may play a role in mediating their hypoten-
sive effects since RDC1 is upregulated in hypoxic astro-
cytes5, and in hypoxic rat lung6. However, binding studies
have demonstrated that RDC1 does not account for
the majority of CGRP binding7, whilst expression of a sta-
ble RDC1 HEK293 cell line did not induce CGRP binding8.
It has since become apparent that RDC1 has relatively
low afﬁnity for adrenomedullin compared to other adreno-
medullin receptors9, and may require the co-expression
of a speciﬁc modulating protein known as receptor
activity modifying protein 1 (RAMP1) to act as a CGRP
receptor9,10.7
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we found that RDC1 is highly expressed in cartilage, sug-
gesting the receptor may have an important physiological
function in this tissue type. Therefore, of great interest is
the proposed role of RDC1 in angiogenesis since vascular
invasion of articular cartilage is known to be a characteristic
of the pathology of osteoarthritis (OA) and is thought to lead
to increased inﬂammation as well as being required for en-
dochondral ossiﬁcation.
RDC1 expression has previously been reported in
the vasculature9. Indeed, it has been considered a tumour
endothelial marker due to its elevated expression in
the tumour endothelial cells of both the brain and
peripheral vasculature11. Furthermore, induction of
angiogenesis in dermal microvascular endothelial cells by
transfection with Kaposi’s sarcoma associated herpesvirus
(KSHV) led to an upregulation in RDC1 expression12.
Indeed recent data have shown that RDC1 is essential
for the KSHV induced transformation of endothelial
cells and it is proposed that RDC1 has the capacity to
function independently of ligand13. RDC1 shares
homology with the viral gene ORF74 encoding a chemoki-
ne receptor, which can signal constitutively in the
absence of ligand. However, constitutive signalling of
ORF74 can be increased or decreased by adding exoge-
nous chemokines14.
The aim of the present study was therefore 2-fold, ﬁrst to
identify and characterise agonists of RDC1 and second to
use these agonists as tools to determine the effect of
RDC1 activation on the expression of a subset of genes
linked to OA.Materials and methods
PREPARATION OF PRIMARY CHONDROCYTES
AND CARTILAGE EXPLANT
Human OA cartilage was obtained following total knee re-
placement operations, whilst normal cartilage was taken
from post-mortem (PM) donors with no previous history of
joint pain. Full ethical consent was obtained from all donors
and families.
To isolate primary chondrocytes, slices of cartilage
were stripped from the femoral condyles and tibial pla-
teaux, cut into small pieces using a scalpel blade and di-
gested in growth media (Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% foetal calf serum
(FCS), penicillin (100 units/ml), streptomycin (100 mg/ml),
2 mM L-glutamine, non-essential amino acids (Invitrogen)
and amphotericin (2.5 mg/ml)) containing 1% collagenase
type IA (0.5e3.0 FALGPA units/mg, Sigma). Following
overnight incubation at 37(C, the sample was ﬁltered to
remove undigested cartilage and chondrocyte cells pel-
leted at 2000 g for 5 min before being resuspended in
growth media.
For the preparation of cartilage explant, full thickness
cartilage was pared from the femoral condyles (medial
and lateral) and tibial plateaux (medial and lateral).
Areas of obvious lesions and badly damaged cartilage
were not used. Slices of cartilage were further processed
using a 3 mm diameter cork borer to generate discs of
full thickness cartilage, which were then pooled. About
48e60 discs were taken from each knee and randomly as-
signed to individual wells of a 96-well plate containingIgG controlAnti-RDC1
HEK
HEK293
Fig. 1. RDC1 expression. Immunohistochemical analysis of RDC1 expression in recombinant RDC1. HEK293293 cell line, compared to an
untransfected HEK293 cell line. Cells were stained with primary anti-RDC1 Lifespan antibody (1:50) or rabbit IgG control (Lifespan) and sec-
ondary anti-rabbit Alexa488 (Molecular Probes) and visualised by confocal microscopy.
599Osteoarthritis and Cartilage Vol. 14, No. 6250 ml aliquots of resting media (phenol red-free DMEM
supplemented with penicillin (100 units/ml), streptomycin
(100 mg/ml), 2 mM L-glutamine, non-essential amino acids
(Invitrogen) and amphotericin (2.5 mg/ml)) and incubated
at 37(C for 24 h.
For treatment with RDC1 agonist, the resting media were
removed, and replaced with 250 ml aliquots of either DMEM
media control, RDC1 agonist (100 mM) in DMEM media or
an inert compound (100 mM) in media and incubated at
37(C for a further 24 h. About 16e20 discs were assigned
to each treatment group, but were maintained in individual
wells for the duration of the experiment. At the end of the
treatment period the discs were pooled for each treatment
and rapidly snap frozen in liquid nitrogen before storing at
80(C for subsequent RNA extraction. The supernatants
were transferred to a 20(C freezer for subsequent matrix
metalloproteinase (MMP) activity measurements.
HOMOLOGY MODELLING
A homology model for the active form of RDC1 was
constructed from the in-active rhodopsin crystal structure
by twisting the sixth helix15. Potential binding sites were
identiﬁed by a space ﬁlling program (PASS) and the Astra-
Zeneca internal compound collection screened virtually
using the docking program FRED (space ﬁlling e two itera-
tions). Using a combination of binding scoring and selecting
a diverse range of compounds a list of 1000 compounds
was generated. Of these, 392 compounds were available
for screening and two hits were found which were expanded
with near neighbours to identify a small cluster of com-
pounds with a common structural identity. These were con-
ﬁrmed as stimulating calcium ﬂux via agonism in a FLIPR
assay.
GENERATION OF RDC1 STABLE CELL LINES
Full length human RDC1 cDNA, including an N-terminal
FLAG tag, was generated from the AstraZeneca cDNA
library by RT-PCR using the following primers with 50
Mlu1 and 30 Not1 restriction sites (shown in bold): forward
50-ACGCGTCATGGACTACAAGGACGACGATGATAAGG-
ATCTGCACCTCTTCGACTAC-30; and reverse 50-GCGG-
CCGCTCATTTGGTGCTCTGCTCC-30. The PCR product
was cloned into an in-house expression vector (Mlu1eNot1)
where RDC1 expression is linked to that of neo with an
internal ribosome entry site (IRES), allowing translation of
two consecutive open reading frames from the same
messenger RNA, driven by a CMV promoter. Vector DNA
was linearised using Hpa1 and introduced into HEK293þ/
Ga16 cells by DNA transfection using Lipofectamine 2000
(Invitrogen). RDC1 expressing cells were selected for
G418 resistance and RDC1 expression conﬁrmed by Taq-
man real-time PCR, and by FACS analysis using a primary
anti-FLAG antibody (1:1000) F3165 (Sigma) and by IHC
(Fig. 1) using a polyclonal RDC1 antibody (LS-A1893,
Lifespan).
INTRACELLULAR CALCIUM TRANSIENT ASSAY (FLIPR)
Cells were seeded into Poly-D-lysine coated 96-well
plates at 5 104 cells per well. After overnight incubation
at 37(C, cells were loaded for 1 h at 37(C with 4 mM
Fluo-4 AM (Molecular Probes) in standard HBSS buffer so-
lution containing 20 mM HEPES, 2 mM CaCl2, 2.5 mMprobenecid and 0.1% BSA. Cells were then washed 3
with standard HBSS buffer solution and transient changes
in [Ca2þ] induced by compound addition were measured
using the FLIPR system (Fluorometric Imaging Plate
Reader, Molecular Devices) up to 180 s. Responses were
measured as peak ﬂuorescent intensity minus basal ﬂuo-
rescent intensity at each concentration of agonist. Sigmoi-
dal doseeresponse curves were ﬁtted with variable Hill
slopes using GraphPad Prism version 3.0 (GraphPad Soft-
ware Inc, CA, USA).
INTRACELLULAR cAMP ASSAY
Intracellular [cAMP] was determined using the BioTrak
Enzymeimmunoassay system (Amersham Biosciences).
In brief, cells were seeded into Poly-D-lysine coated
96-well plates at 2 104 cells per well. After overnight
incubation at 37(C, the culture medium was removed
and cells incubated for 1 h in phosphate buffered saline
(PBS) containing compounds with or without forskolin
(100 mM). Following incubation, the wells were aspirated
and the cells lysed. Intracellular [cAMP] was then deter-
mined from the cell lysate according to the manufacturer’s
instructions.
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Fig. 2. Ca2þ response to RDC1 agonists in RDC1 HEK293 cell
lines. RDC1 HEK293, RDC1 Ga16 HEK293 and control HEK293
cells were stimulated with compound agonists at 1, 3, 10, 30, 100
and 300 mM. Values are mean maximal responses (n¼ 3). The
transient Ca2þ response was detected by FLIPR. (a) Activity of
RDC1 agonist compound 12 in RDC1. HEK293 and untransfected
HEK293 cells. (b) Comparison of potency of compound agonists 1,
5, 8 and 12.
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Supernatants from cartilage explants were analysed for
MMP activity using the Fluorescence Resonance Emission
Transfer (FRET) peptide substrate MCA-Pro-Cha-Gly-Nva-
His-Ala-Dpa-NH2. In brief, 25 ml of each supernatant was in-
cubated with the FRET peptide (33.3 mM) in assay buffer
(0.1 M TriseHCl, 0.1 M NaCl, 10 mM CaCl2, 0.05% Brij
35, pH 7.5) for 24 h at 37(C. The ﬂuorescence of the re-
leased MCA reporter was then measured at lex 328 nm
and lem 398 nm. MMP activity was quantiﬁed by compar-
ing to an MMP13 standard. Total MMP was determined
by prior activation with APMA (4 mM) and the data analysed
using Softmax Pro.
siRNA TRANSFECTION OF HEK293 CELL LINES AND PRIMARY
CHONDROCYTES
HEK293 cells were transfected with either a siRNA
duplex directed against RDC1 (Dharmacon) or a non-
targeting control siRNA at a ﬁnal concentration of 100 nM
using Lipofectamine 2000 (Invitrogen). Following 24 h
post-transfection cells were stimulated with compound
5 (100 mM) and total RNA extracted and stored at 80(C
for subsequent analysis. Human primary chondrocytes
were transfected with RDC1 siRNA duplexes (SMART
duplexes, Dharmacon) at a ﬁnal concentration of 10 nM
using 3 mg/ml Atufect01 lipid (Atugen). Scrambledglyceraldehyde-3 phosphate dehydrogenase (GAPDH)
(Ambion) was used as a negative control. Following 120 h
post-transfection, cells were stimulated for 24 h with either
30 or 100 mM compound 5 and total RNA was extracted
and stored at 80(C for subsequent gene expression
analysis.
GENE EXPRESSION ANALYSIS IN PRIMARY CHONDROCYTES
AND CARTILAGE EXPLANT
Total RNA was extracted from cell lines using 96
Rneasy kit (Qiagen) or from cartilage explant discs
using Trizol (Invitrogen) according to the manufacturer’s
instructions and then quantiﬁed using a Bioanalyser
(Agilent). Taqman primers and probes were obtained as
pre-validated Assays on Demand (Applied Biosystems).
For analysis of RDC1 expression, the human cDNA
sequence was obtained from GenBank and primers
(forward 50 GGCTATGACACGCACTGCTACA 30 and re-
verse 50 TGGTTGTGCTGCACGAGACT 30) and Taqman
probe (50 CTGGCCATTGCCGACCTGTGG 30) designed
using Primer Express version 2.0 Software (Perkin-Elmer).
Taqman probes were labelled with a reporter dye, FAM
(6-carboxyﬂuorescein), at the 50 end, and a ﬂuorescent
quencher dye TAMRA (6-carboxy-tetramethyl-rhodamine)
at the 30 end. Real-time PCR was performed using
the one-step RT-PCR Kit (Qiagen) in a MicroAmp 96-well
Reaction Plate. Each well contained 25 ng total RNA,a b
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Fig. 3. RDC1 compound agonists exhibit partial Gi coupling. (a) Effect of compound agonists 1, 5, 8 and 12 (10e100 mM) on cAMP stimulation
in HEK293 RDC1 cells. Bars represent mean S.E.M. (b) Effect of compound agonists on the inhibition of the forskolin cAMP induction. In-
tracellular cAMP was measured using a BioTrak kit (Amersham). Bars represent mean S.E.M. *¼Signiﬁcantly different (P< 0.05) from
the forskolin cAMP response. (c) Inhibition of compounds 5 and 12 Ca2þ response in HEK293 RDC1 cells following deactivation of Gq pro-
teins by overnight incubation with pertussis toxin (100 ng/ml). Bars represent mean S.E.M. (n¼ 6). *¼Signiﬁcantly different from untreated
control HEK293 RDC1 cells.
601Osteoarthritis and Cartilage Vol. 14, No. 6300 nM (forward and reverse) primers and 125 nM Taqman
probe in a reaction volume of 25 ml. All sample and non-
template control reactions were performed in the ABI
Prism 7700 Sequence Detection System (Applied Biosys-
tems) in triplicate. For each primer/probe set a series
of standard curves was obtained using a standard
control sample of RNA. Comparative slopes of the relation-
ship between log[RNA] and Ct (gradient¼3.3) for both
the gene of interest and the housekeeping genes 18S
and GAPDH indicated that the comparative Ct method
(DDCt) could be used for the relative quantiﬁcation of
gene expression.
The simultaneous expression of 96 pre-selected genes
was analysed from total RNA (850 ng) using a 384-well
Taqman Microﬂuidics card (Applied Biosystems) containing
4 96 Taqman probe sets. Ct values were normalised to
the housekeeping gene b-actin and gene expression mea-
sured relative to a media control.
STATISTICAL ANALYSIS
Analysis of variance (ANOVA) and Student’s t tests were
used to determine signiﬁcance, with signiﬁcance accepted
as P< 0.05. Values are shown as mean S.E.M.Results
IDENTIFICATION OF RDC1 RECEPTOR AGONISTS
Using a homology model of RDC1, based on the
active conformation of the bovine rhodopsin receptor,
a virtual screen of in-house compounds was performed.
These compounds were then screened for their ability to in-
voke a Ca2þ response at a single concentration of 30 mM in
RDC1 HEK293 and RDC1 Ga16 HEK293 cell lines, which
resulted in a single hit. Near neighbour analysis identiﬁed
a further 500 compounds with potentially improved activity.
Of these 500 compounds, four were selected for further
analysis based on their potency in the recombinant
RDC1 cell line and the absence of a Ca2þ response in an
untransfected HEK293 cell line [Fig. 2(a)]. The compounds
also elicited a Ca2þ response in the RDC1 Ga16 cell line,
although this was markedly lower. Potency [Fig. 2(b)] was
in the order of compound 12 (EC50¼ 35 mM)> 5
(EC50¼ 86 mM)> 8 (EC50¼ 161 mM)> 1 (EC50¼ 166 mM).
RDC1 COUPLES THROUGH Gi PROTEIN
The transient induction of Ca2þ following compound
addition to the RDC1 HEK293 cell line, suggested that-5.0 -4.5 -4.0 -3.5 -3.0
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Fig. 4. RDC1 is expressed and is active in primary chondrocytes. (a) Human primary chondrocytes were prepared from a normal knee and the
Ca2þ response to compounds 1, 5, 8 and 12 (30e300 mM) measured by FLIPR. Values are mean maximal response (n¼ 3). (b) Primary
chondrocytes stained using the polyclonal RDC1 antibody or IgG control (1:200).
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Comparison of the maximal FLIPR response of RDC1 agonist in
primary chondrocytes and in HEK293 RDC1 cell line
Compound Fu (300 mM)
Chondrocytes HEK293 RDC1
5 7750* 30075
12 4200 28435
1 3619 25354
8 2800 22003
*Mean maximal ﬂuorescent units recorded following agonist
addition.RDC1 can couple (at least partly) via Ca2þ signalling G-
proteins. RDC1 coupling was further studied using
a cAMP assay (Amersham Biosciences) to ascertain
whether there was any evidence to suggest RDC1 couples
through Gs or Gi proteins. Following compound addition
to RDC1 HEK293 cells there was no induction of cAMP,
suggesting that RDC1 does not couple through Gs
[Fig. 3(a)]. However, each of the compounds signiﬁcantly
diminished the forskolin cAMP response (P< 0.05, n¼ 3)
suggesting that RDC1 couples, at least partly through
Gi, following compound activation [Fig. 3(b)]. Furthermore,
deactivation of Gi proteins in the RDC1 HEK293 cell
line by overnight incubation with pertussis toxin markedly
reduce the compound Ca2þ response (42% and 61%
for compound 5 and 12, respectively, P< 0.01, n¼ 6),a
b
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Fig. 5. RDC1 is highly expressed in cartilage tissue, but is not differentially expressed in OA. (a) Biodistribution of RDC1 mRNA expression. (b)
Expression of RDC1 in human normal (n¼ 9) and osteoarthritic (n¼ 7) cartilage samples. Bars represent mean S.E.M. RDC1 expression was
determined by real-time PCR using Taqman primers and probes and normalised to the housekeeping gene 18S.
603Osteoarthritis and Cartilage Vol. 14, No. 6again indicating a signiﬁcant proportion of Gi coupling
[Fig. 3(c)].
RDC1 RECEPTOR IS FUNCTIONALLY ACTIVE IN PRIMARY
HUMAN CHONDROCYTES
Primary chondrocytes were prepared from normal
cartilage taken from the knee, PM, passaged twice and
then seeded for FLIPR analysis. Each of the agonist
compounds elicited a FLIPR response at 100 mM and
above. However, there was no FLIPR response to an inert
control compound at 100 mM, which was chosen based on
its inactivity in a number of previous biological screens
(Fig. 4). Based on the magnitude of response, compounds
5 and 12 were the more efﬁcacious than either compound 1
or 8, in agreement with that found in the RDC1 HEK293 cell
line (Table I). Furthermore, similar to the recombinant RDC1
HEK293 cell line, deactivation of Gi protein using pertussis
diminished the compound Ca2þ response (data not shown).
RDC1 TISSUE EXPRESSION PROFILE
Having established that the homology model compounds
act as RDC1 ligands, we sought to investigate the biological
role of RDC1. Analysis of the tissue expression of RDC1 by
Taqman real-time PCR demonstrated that expression of
RDC1 was predominant in cytoskeletal tissues such as tho-
racic tissues with particularly high expression in cartilage,
bone and synovium [Fig. 5(a)], suggesting a possible role
for the receptor in cartilage tissue. To examine whether
RDC1 expression was differentially regulated in OA, RNA
was extracted from nine normal knee samples and
seven OA knees. Taqman analysis demonstrated that
RDC1 expression was not signiﬁcantly different (P¼ 0.27)
between OA (2.4 0.2, n¼ 7) and normal (2.4 0.2,
n¼ 9), indicating that if RDC1 plays a role in the develop-
ment of OA it is not regulated by the level of receptor
expression [Fig. 5(b)].
ACTIVATION OF RDC1 INDUCES THE EXPRESSION OF GENES
THAT REGULATE CHONDROCYTE HYPERTROPHY AND
MATRIX TURNOVER
To examine the potential role that RDC1 might play in the
development/regulation of OA, we examined the effect of
RDC1 activation on a subset of genes differentially regu-
lated in OA. Human chondrocytes, prepared from a normal
human knee, were incubated for 24 h with RDC1 agonist
(100 mM), or the inert compound (100 mM).
Expression analysis showed that the RDC1 agonist in-
duced a number of signiﬁcant changes in the expression
of genes associated with chondrocyte hypertrophy, mineral-
isation and matrix turnover (Table II). Of particular note was
the increase in expression of the MMPs. MMP1 was upre-
gulated 12-fold, whilst MMP14 and MMP2 were both upre-
gulated 2-fold. However, there was no change in the
expression of the aggrecanases, ADAMTS4 or ADAMTS5.
In addition, there was a downregulation of particular colla-
gens, with collagen types 1, 2, 3, 9 and 11 all downregu-
lated between 2- and 3-fold. Also of note, was the
elevation in expression of genes associated with chondro-
cyte hypertrophy, matrix mineralisation and angiogenesis,
with a 3-fold upregulation in collagen type 10 and osteocal-
cin, a 9-fold increase in osteopontin and a 7-fold increase in
vascular endothelial growth factor (VEGF).
To further explore these effects, and to more closely
mimic the in vivo condition, human cartilage explant fromthree normal and three OA knees was prepared and incu-
bated for 24 h with either media control, RDC1 agonist
(100 mM) or the inert compound (100 mM) and gene expres-
sion determined by real-time PCR. As was observed in
chondrocytes, RDC1 agonist induced expression of a num-
ber of MMPs, with MMP1, 2, 3, 13 and 14 all upregulated in
both OA and normal cartilage. Likewise, BMP2 and VEGF
were also both induced by RDC1 agonist in both normal
and OA explant tissue [Fig. 6(aec)]. Of interest were the dif-
ferential effects of RDC1 agonist on collagen type 2 (Col2)
and aggrecan expression between OA and normal carti-
lage. In OA tissue, RDC1 agonist downregulated Col2
and aggrecan by 26% and 30%, respectively, mimicking
that seen in primary chondrocytes. However, no signiﬁcant
effect of RDC1 agonist on either Col2 or aggrecan was de-
tected in normal explant tissue [Fig. 6(d)].
TREATMENT OF CARTILAGE EXPLANT WITH RDC1 AGONIST
INCREASES TOTAL MMP ACTIVITY
Treatment of cartilage explant with the RDC1 agonist sig-
niﬁcantly (P< 0.01) upregulated total MMP activity by
146%, 147% and 95%, respectively, in three different PM
donors. There was no effect of the inert compound on
MMP activity (Fig. 7).
EFFECTS OF RDC1 AGONISTS ON GENE EXPRESSION ARE
MEDIATED BY RDC1
To examine whether the observed gene changes were
due to speciﬁc signalling through the RDC1 receptor we ini-
tially examined the effect of RDC1 agonist on the recombi-
nant RDC1 cell line compared to an empty control HEK293
cell line. Following a 24 h incubation with RDC1 agonist
there was a 4-fold upregulation in MMP1 expression, and
a 1.5-fold downregulation in Col2 expression in the RDC1
HEK293 cells, in line with that observed in primary chondro-
cytes. However, there was no effect on either MMP1 or
Col2 expression following the incubation of RDC1 agonist
on the control HEK293 cells, suggesting that the observed
gene changes in both MMP1 and Col2 were mediated
through RDC1 (Fig. 8).
To further validate that the observed gene changes
were due to speciﬁc signalling through the RDC1 receptor,
we examined the effect of reducing expression of the
Table II
Summary of gene expression changes induced by RDC1 compound
agonist in primary human chondrocytes
Gene Fold induction Fold reduction
Aggrecan 3.7
Chondromodulin 2.1
Col2 3.2
Col3 2.2
Col9 2.1
Col11 2.3
Col10 2.7
Osteopontin 9.0
BMP2 5.6
Osteocalcin 2.9
IL-8 3
MMP14 2.1
MMP1 12.1
MMP2 2
VEGF 6.7
Genes where fold change of >2.0 accepted.
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605Osteoarthritis and Cartilage Vol. 14, No. 6RDC1 receptor using siRNA antisense. Transfection of
RDC1 siRNA into RDC1 HEK293 cells, resulted in a 85% re-
duction in RDC1 expression, relative to non-targeting control
siRNA [Fig. 9(a);P< 0.01], and had the effect of reducing the
Ca2þ response to RDC1 agonist by 30% (P< 0.05), com-
pared to cells transfected with the siRNA control [Fig. 9(b)].
Transfection of RDC1 siRNA into human primary chon-
drocytes led to an 86% reduction in RDC1 expression after
120 h (P< 0.01) and blocked the effects of 24 h stimulation
with RDC1 agonist on the induction of MMP1 and VEGF,
and on the downregulation of Col2 [Fig. 9(c)]. Expression
of the related chemokine receptors (CXCR2 and CXCR4)
was not effected by the RDC1 siRNA duplex, suggesting
that the siRNA duplex was speciﬁc (data not shown).
Discussion
Using a homology model of the RDC1 receptor we have
identiﬁed and characterised a number of compounds that
act as RDC1 agonists. The RDC1 agonists produced a tran-
sient Ca2þ response in a stable RDC1 HEK293 cell line,
which was signiﬁcantly reduced upon knockdown of
RDC1 expression with siRNA antisense transfection.
A tissue expression proﬁle of RDC1 showed high expres-
sion in cytoskeletal and cartilage tissues. Analysis of the
FLIPR response in human primary chondrocytes showed
that the RDC1 agonists elicited a response, which in terms
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RDC1 was likely to play a role in the regulation and/or devel-
opment of OA, human primary chondrocytes and cartilage
explant tissues from both PM andOA donors were treated ei-
ther with RDC1 agonist or an inert control compound for 24 h.
Treatment of primary chondrocytes with RDC1 agonist com-
pound had a profound effect on the expression of a number
of genes believed to regulate articular cartilage matrix turn-
over, chondrocyte hypertrophy and induction of angiogene-
sis. Of note was the induction of MMP1 and VEGF and the
downregulation in Col2, all of whichwere prevented following
transfection of primary chondrocytes with a speciﬁc RDC1
siRNA duplex. Treatment of both normal and OA cartilage
explant with compound agonist also led to increased MMP
expression (MMP1, 2, 3, 13 and 14), which was mirrored
by a 100e150% increase in MMP activity in normal cartilage.
MMPs have long been considered to play a major regula-
tory role in maintaining cartilage homeostasis and the
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associated with early degenerative joint disease in both hu-
man16e19 and in animal models20e24. Our ﬁnding in the
present study that RDC1 activation leads to an induction
of MMPs with no change in either of the aggrecanases
(ADAMTS4 or ADAMTS5) mimics the gene expression
changes reported in a previous study which found that OA
induced in rabbit by the severing of the anterior cruciate
knee ligament resulted in a rapid induction of MMP1, 3
and 13 expression, with no change in aggrecanase25.
MMP1, and in particular, MMP13 have been purported to
be biomarkers for early degenerative joint disease. Indeed,
sites of Col2 degradation, the major component of articular
cartilage, are localised to areas of increased MMP1 and
MMP13 expression26. MMP13 is highly upregulated in dis-
ease and its ability to degrade Col2 more effectively than
other MMPs suggests a major role for this protease incartilage degradation27,28. However, it has also been re-
ported that in addition to elevated proteolysis of Col2 in
OA, there is a marked increase in newly-synthesised Col2
and its type 2A variant, which is not expressed in healthy
cartilage. Signiﬁcantly, increased proteolysis of newly-syn-
thesised cartilage has been shown to be as a result of
MMP1 activity29. Our ﬁnding that both MMP1 and MMP13
expression is increased with RDC1 activation suggests
that a therapeutic strategy aimed at inhibiting RDC1 signal-
ling could be effective not only in suppressing cleavage of
resident Col2, but also in suppressing cleavage of mole-
cules involved in cartilage repair.
In addition to the upregulation in MMP expression, RDC1
activation also led to a downregulation in Col2 and in aggre-
can expression. Whilst the upregulation in MMPs suggests
an increase in the proteolysis of matrix components, the
downregulation in expression of both Col2 and aggrecan
607Osteoarthritis and Cartilage Vol. 14, No. 6in OA explant tissue also implies that RDC1 activation leads
to a reduction in matrix synthesis. Furthermore, since it has
been reported that aggrecan protects Col2 from proteolytic
cleavage30, the reduction in aggrecan expression may in
turn also result in an increase in MMP-induced Col2
degradation.
One of the features of the pathology of OA cartilage is the
appearance of hypertrophic chondrocytes and also in-
creased angiogenesis of the cartilage. Hypertrophic chon-
drocytes are also known to release a number of
angiogenic factors31 including VEGF32, which in turn is
thought to lead to increased inﬂammation as well as being
required for endochondral ossiﬁcation. Our ﬁnding that acti-
vation of RDC1 leads to increased expression of a number
of hypertrophic factors (collagen type 10, IL-8, osteocalcin,
and osteopontin) and the potent angiogenic factor VEGF,
which is present in OA cartilage, but largely absent in adult
cartilage tissue33, suggests that RDC1 may play a role in
mediating both of these effects, effectively driving the chon-
drocytes towards a hypertrophic state characteristic of early
OA. Hypertrophic chondrocytes are normally found in carti-
lage undergoing endochondral ossiﬁcation and so are
highly undesirable in fully developed adult cartilage where
further ossiﬁcation may compromise the mechanical proper-
ties of the overlying cartilage matrix. This may also be re-
ﬂected by the increased expression of the bone
morphogenetic protein, BMP2, following RDC1 activation,
which was ﬁrst identiﬁed by its ability to induce bone forma-
tion, and has previously been reported to be upregulated in
osteoarthritic and damaged cartilage34,35.
Clearly, future efforts to determine the physiological
ligand for RDC1 are of great importance. The recent publi-
cation by Balabanian et al.36 reports that the CXCR4 ligand,
SDF1a, binds to RDC1 receptors with greater afﬁnity
(Kd¼ 0.4 nM) than that previously reported for CXCR4,
and is capable of activating chemotaxis in RDC1 express-
ing T-cells. In our functional FLIPR assay, SDF1a did not in-
voke a Ca2þ response in either RDC1 HEK293 or in
a RDC1 Ga16 cell line where the Ca2þ response is forced
by the over-expression of the promiscuous G-protein. How-
ever, this does not exclude the possibility that SDF1a may
bind to and signal via RDC1 given a particular G-protein
background. Further work is therefore required to establish
whether SDF1a is the functional physiological ligand for
RDC1 in cartilage tissue.
In summary, we have generated a number of RDC1 ago-
nists based on a bovine rhodopsin homology model of
RDC1. Most importantly, given the high expression of
RDC1 in cartilage, we have demonstrated that the activa-
tion of RDC1 in human chondrocytes and in cartilage
explant tissue impacts on the expression of a number of
genes associated with chondrocyte hypertrophy, angiogen-
esis and increased matrix degradation, factors that are
indicative of the early degenerative development of OA.
This data should be of considerable value in attempting to
develop future therapeutics.
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